Zobrazeno 1 - 10
of 26
pro vyhledávání: '"F. Boussoulade"'
Autor:
Sandrine Rochette-Eribon, P. Morata, Olivier Garraud, F. Boussoulade, V. Bost, Patricia Chavarin, Sophie Acquart, P. Fabrigli, Fabrice Cognasse, C. Argaud
Publikováno v:
Transfusion Clinique et Biologique. 21:31-36
In France, three varieties of therapeutic plasma are being processed, distributed and delivered, currently; however, many more varieties are in use worldwide, which go by the property of labile blood component or plasma derived medicines. For one typ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e97b3c1d4cb62bb91da07f816ebe68c
https://doi.org/10.1016/j.tracli.2014.01.001
https://doi.org/10.1016/j.tracli.2014.01.001
Autor:
C. DePutter, Patricia Chavarin, P. Fabrigli, M. Vidal, Olivier Garraud, F. Boussoulade, Sophie Acquart, C. Argaud
Publikováno v:
Transfusion Clinique et Biologique. 18:472-477
In the past few years, pathogen reduction technologies for labile blood products have been part of the enhancement of global transfusion safety regarding residual risks of transmitting infectious pathogens. Having carried out a feasibility study for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4a732fb1dffdb0e5799d336aa2cfad2
https://doi.org/10.1016/j.tracli.2011.04.002
https://doi.org/10.1016/j.tracli.2011.04.002
Autor:
Patricia Chavarin, H. Odent-Malaure, Fabrice Cognasse, D. Legrand, H. Benamara, V. Bost, Olivier Garraud, C. Chabre, P. Fabrigli, F. Boussoulade
Publikováno v:
Vox sanguinis. 109(4)
Amotosalen-HCl-UVA (AI) is a process to inactivate pathogens in therapeutic plasma (FFP). Tolerance is the main residual issue in FFP transfusion, and only large series observations are powered enough to identify significantly elevated levels of haza
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7047fd5a28679face0857425c000b21d
https://pubmed.ncbi.nlm.nih.gov/26031441
https://pubmed.ncbi.nlm.nih.gov/26031441
Autor:
Patricia Chavarin, L. Lin, Olivier Garraud, F. Boussoulade, C. de Putter, C. Argaud, Fabrice Cognasse, S. Acquart, C. Ripaud, M. Vidal
Publikováno v:
Vox Sanguinis. 100:247-249
Background and Objectives INTERCEPT Blood System™ is a pathogen inactivation system for blood components. The initial approval required a platelet component to be suspended in a combination of plasma and Platelet additive Solution/PAS-III. Improved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ad599bd1313c0a41e7d9dd1e3a9133f
https://doi.org/10.1111/j.1423-0410.2010.01389.x
https://doi.org/10.1111/j.1423-0410.2010.01389.x
Autor:
O, Garraud, P, Chavarin, F, Boussoulade, P, Morata, S, Rochette-Eribon, S, Acquart, P, Fabrigli, C, Argaud, V, Bost, F, Cognasse
Publikováno v:
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine. 21(1)
In France, three varieties of therapeutic plasma are being processed, distributed and delivered, currently; however, many more varieties are in use worldwide, which go by the property of labile blood component or plasma derived medicines. For one typ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a539844055895cf6b0308bc3543ce834
https://pubmed.ncbi.nlm.nih.gov/24560485
https://pubmed.ncbi.nlm.nih.gov/24560485
Autor:
P, Chavarin, C, DePutter, F, Boussoulade, S, Acquart, M, Vidal, C, Argaud, P, Fabrigli, O, Garraud
Publikováno v:
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine. 18(4)
In the past few years, pathogen reduction technologies for labile blood products have been part of the enhancement of global transfusion safety regarding residual risks of transmitting infectious pathogens. Having carried out a feasibility study for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::67830ba1f028dd89dd6a954bd39cb581
https://pubmed.ncbi.nlm.nih.gov/21783400
https://pubmed.ncbi.nlm.nih.gov/21783400
Autor:
P, Chavarin, F, Cognasse, C, Argaud, M, Vidal, C, De Putter, F, Boussoulade, C, Ripaud, S, Acquart, L, Lin, O, Garraud
Publikováno v:
Vox sanguinis. 100(2)
INTERCEPT Blood System™ is a pathogen inactivation system for blood components. The initial approval required a platelet component to be suspended in a combination of plasma and Platelet additive Solution/PAS-III. Improved platelet storage has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::25a392cd916b065f11deca15e325ccc8
https://pubmed.ncbi.nlm.nih.gov/20735811
https://pubmed.ncbi.nlm.nih.gov/20735811
Publikováno v:
Transfusion Clinique et Biologique. 22:221
Le procede INTERCEPT Blood System (Cerus), permet d’inactiver les pathogenes dans les plaquettes et les plasmas en utilisant amotosalen et UVA. Cerus a sollicite l’EFS pour valider la version 5 du logiciel de l’INT100. Le site pilote devait uti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0681ca990e2cadfd71f0915ebe8081c0
https://doi.org/10.1016/j.tracli.2015.06.022
https://doi.org/10.1016/j.tracli.2015.06.022
Autor:
Olivier Garraud, Patricia Chavarin, P. Fabrigli, Bernard M. Lamy, Sophie Acquart, Fabrice Cognasse, F. Boussoulade
Publikováno v:
Transfusion. 46(7)
BACKGROUND: Blood platelets (PLTs) link the processes of hemostasis and inflammation. Recent studies have demonstrated that PLTs promote immunity and inflammation mainly by means of the CD40/CD40L pathway. Our objective was to describe the accumulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41041bd623c4c9ba5c706b3888fb7929
https://pubmed.ncbi.nlm.nih.gov/16836566
https://pubmed.ncbi.nlm.nih.gov/16836566
Autor:
F. Flourie, S. Duboeuf, P. Moreton, A. Benamara, Patricia Chavarin, M.N. Varlet, Olivier Garraud, F. Boussoulade, L. Absi
Publikováno v:
Transfusion Clinique et Biologique. 20:273-274
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b13294b7190c47b42842b23f3cfcace
https://doi.org/10.1016/j.tracli.2013.04.073
https://doi.org/10.1016/j.tracli.2013.04.073